WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience AutoMate Scientific
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
The Journal of Neuroscience, November 2, 2005, 25(44):10180-10187; doi:10.1523/JNEUROSCI.3591-05.2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental data
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liang, X.
Right arrow Articles by Andreasson, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liang, X.
Right arrow Articles by Andreasson, K.

 Previous Article  |  Next Article 

Neurobiology of Disease
Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease

Xibin Liang,1 Qian Wang,1 Tracey Hand,1 Liejun Wu,1 Richard M. Breyer,3 Thomas J. Montine,4 and Katrin Andreasson1,2

Departments of 1Neurology and 2Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, 3Department of Medicine, Division of Nephrology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, and 4Department of Pathology, University of Washington, Seattle, Washington 98104

Epidemiological studies demonstrate that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) in normal aging populations reduces the risk of developing Alzheimer's disease (AD). NSAIDs inhibit the enzymatic activity of cyclooxygenase-1 (COX-1) and inducible COX-2, which catalyze the first committed step in the synthesis of prostaglandins. These studies implicate COX-mediated inflammation as an early and potentially reversible preclinical event; however, the mechanism by which COX activity promotes development of AD has not been determined. Recent studies implicate the prostaglandin E2 (PGE2) E prostanoid subtype 2 (EP2) receptor in the development of the innate immune response in brain. Here, we report that deletion of the PGE2 EP2 receptor in the APPSwe-PS1{Delta}E9 model of familial AD results in marked reductions in lipid peroxidation in aging mice. This reduction in oxidative stress is associated with significant decreases in levels of amyloid-{beta} (A{beta}) 40 and 42 peptides and amyloid deposition. Aged APPSwe-PS1{Delta}E9 mice lacking the EP2 receptor harbor lower levels of {beta} C-terminal fragments, the product of {beta}-site APP cleaving enzyme (BACE1) processing of amyloid precursor protein. Increases in BACE1 processing have been demonstrated in models of aging and AD and after oxidative stress. Our results indicate that PGE2 signaling via the EP2 receptor promotes age-dependent oxidative damage and increased A{beta} peptide burden in this model of AD, possibly via effects on BACE1 activity. Our findings identify EP2 receptor signaling as a novel proinflammatory and proamyloidogenic pathway in this model of AD, and suggest a rationale for development of therapeutics targeting the EP2 receptor in neuroinflammatory diseases such as AD.

Key words: prostaglandin; receptor; transgenic; inflammation; A{beta} peptide; Alzheimer's disease

Received Aug 24, 2005; revised September 20, 2005; accepted September 23, 2005.




This article has been cited by other articles:


Home page
 FASEB J.Home page
O. Firuzi, J. Zhuo, C. M. Chinnici, T. Wisniewski, and D. Pratico
5-Lipoxygenase gene disruption reduces amyloid-{beta} pathology in a mouse model of Alzheimer's disease
FASEB J, April 1, 2008; 22(4): 1169 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Park, P. Zhou, R. Pitstick, C. Capone, J. Anrather, E. H. Norris, L. Younkin, S. Younkin, G. Carlson, B. S. McEwen, et al.
Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein
PNAS, January 29, 2008; 105(4): 1347 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. P. Kellogg, T. D. Wiggin, D. D. Larkin, J. M. Hayes, M. J. Stevens, and R. Pop-Busui
Protective Effects of Cyclooxygenase-2 Gene Inactivation Against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fiber Loss in Experimental Diabetes
Diabetes, December 1, 2007; 56(12): 2997 - 3005.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Hoshino, T. Nakaya, T. Homan, K.-i. Tanaka, Y. Sugimoto, W. Araki, M. Narita, S. Narumiya, T. Suzuki, and T. Mizushima
Involvement of Prostaglandin E2 in Production of Amyloid-beta Peptides Both in Vitro and in Vivo
J. Biol. Chem., November 9, 2007; 282(45): 32676 - 32688.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Sugimoto and S. Narumiya
Prostaglandin E Receptors
J. Biol. Chem., April 20, 2007; 282(16): 11613 - 11617.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
N. Sang and C. Chen
Lipid Signaling and Synaptic Plasticity
Neuroscientist, October 1, 2006; 12(5): 425 - 434.
[Abstract] [PDF]


-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help
-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-